GlassScriptPhysician profile
Darko Zdilar
NPI 1871527903
$9,970.27
in general payments reported to CMS, 2019-2025
31 companies · $1,903 in 2025
The $1,903 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $738 · 2021: $1,527 · 2022: $1,471 · 2023: $1,641 · 2024: $1,672 · 2025: $1,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,189 · Education: $26.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,189.35 |
| Education | $26.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,684.07 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,464.55 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,017.69 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $721.41 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $653.25 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $569.05 | 2019-2024 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $560.81 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $503.93 | 2019-2025 | Rexulti |
| Allergan, INC. | $453.78 | 2019-2020 | |
| Alkermes, INC. | $406.94 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $268.16 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $262.51 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $254.45 | 2020-2022 | |
| Corium, LLC | $243.13 | 2021-2023 | Azstarys |
| Livanova USA, INC. | $172.17 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $129.22 | 2020-2021 | |
| Neos Therapeutics, LP | $88.19 | 2020-2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $83.78 | 2021 | |
| Ironshore Pharmaceuticals INC. | $60.13 | 2022-2023 | Jornay Pm |
| Almatica Pharma LLC | $56.64 | 2021-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $49.07 | 2020-2022 | |
| Indivior INC. | $44.15 | 2022 | |
| Supernus Pharmaceuticals, INC. | $39.06 | 2022 | |
| Noven Therapeutics, LLC | $34.69 | 2023 | Xelstrym |
| Brainsway USA INC | $28.21 | 2023 | |
| Shire North American Group INC | $28.14 | 2019 | |
| Sage Therapeutics, LLC | $23.72 | 2021 | |
| Owp Pharmaceuticals, INC. | $20.16 | 2019 | |
| Tris Pharma INC | $19.40 | 2022 | |
| Adlon Therapeutics L.P. | $17.20 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darko Zdilar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.